Ivabradín Teva Slovakia (Ivabradine)

Ivabradine selectively blocks the funny (If) current in the sinoatrial node, the heart’s natural pacemaker. By inhibiting this current, the drug slows the spontaneous depolarisation of pacemaker cells, reducing the heart rate without affecting the strength of cardiac contraction.

The specific dose of Ivabradín Teva Slovakia is determined by the prescribing clinician based on the patient’s clinical condition, heart‑rate response, and tolerance. Dosage adjustments are made according to individual therapeutic goals and safety monitoring.

The safety of ivabradine in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both ivabradine and beta‑blockers lower heart rate, but ivabradine does so by selectively inhibiting the If current without affecting myocardial contractility or blood pressure. Beta‑blockers act on adrenergic receptors and have broader cardiovascular effects, which may be advantageous or limiting depending on the patient’s profile.

Ivabradín Teva Slovakia should be stored below 25 °C in its original packaging, protected from moisture and direct sunlight. Do not store in a bathroom or near heat sources, and keep the container tightly closed when not in use.

The medication is taken orally, usually with or without food, as directed by the prescriber. Tablets should be swallowed whole with a glass of water and not crushed or chewed unless otherwise instructed.

The most serious risks include severe bradycardia, atrial fibrillation, symptomatic hypotension, and rare visual disturbances that may affect vision. Patients should be monitored for these events, especially during dose initiation and titration.

Ivabradine is contraindicated in patients with acute decompensated heart failure, severe hypotension, sick‑sinus syndrome, sinoatrial block, or those taking strong CYP3A4 inhibitors. It should also be avoided in individuals with known hypersensitivity to ivabradine or any of its excipients.